BeNeLuxBelgiumNetherlandsLuxembourg

EPO enhancer identified

19.02.2008

Leuven/Geneva – Belgian and Swiss researchers have discovered a protein factor that could improve the response rate to anemia blockbuster erythropoietin (EPO). In mice, they found that the protein product of growth arrest-specific gene 6 (Gas6) was released in response to Epo, and that Gas6 enhanced Epo receptor signaling by activating the serine-threonine kinase Akt in murine erythro­blasts. In the absence of Gas6, erythroid progenitors and erythroblasts were hyporesponsive to the survival activity of Epo, and failed to restore hematocrit levels in response to anemia. In a transgenic mouse model of chronic anemia caused by insufficient Epo production, Gas6 synergised with Epo in restoring hematocrit levels. Drugs that promote Gas 6 expression might therefore be a means to treat sensitive non responders to Epo.

BeNeLuxBelgiumNetherlandsLuxembourg

16.12.2011

Mechelen - Galapagos NV confirms its status as one of Europe best drug discovery companies. The Belgian biotech received €4 million as the first milestone payments from French Servier for the discovery of new targets for...

BeNeLuxBelgiumNetherlandsLuxembourg

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted...

BeNeLuxBelgiumNetherlandsLuxembourg

02.12.2011

Zwijnaarde/Rotterdam – In vivo camelid antibody specialist arGEN-X BVBA has baged €27.5 million of fresh capital for development of its preclinical monoclonal antibody pipeline. The round B financing of the 3 year-old company,...

BeNeLuxBelgiumNetherlandsLuxembourg

28.11.2011

Brussels/Ghent – Belgian researchers have demonstrated that tumour cells secrete the angiogenesis factor VEGF to create a microenvironment that fosters proliferation of cancer stem cells. In mice with squamous cell carcinoma,...

BeNeLuxBelgiumNetherlandsLuxembourg

23.11.2011

Mechelen – Belgian drugmaker Galapagos NV has reported impressive results of a proof-of-concept trial with its oral janus kinase 1 blocker GLPG0634 + Methothrexate in patients with active rheumatoid arthritis. In the 24 patients...

BeNeLuxBelgiumNetherlandsLuxembourg

18.11.2011

Naarden – Enzyme replacement therapies specialist Oxyrane NV raised €20 million in a series D round of financing. The therapies are designed to treat lysosomal storage diseases, a class of more than forty rare inherited diseases....

BeNeLuxBelgiumNetherlandsLuxembourg

14.11.2011

Hilden/Venlo – Sample and assay technologies provider Qiagen N.V. is set to eliminate about 10% of its current global workforce of 3,800 employees. The company says the cuts are one result of implementing a project aimed at...

BeNeLuxBelgiumNetherlandsLuxembourg

09.11.2011

New York/Ghent - Big brother is gone. Belgian biotech Ablynx regained the rights for nanobodies targeting TNF-alpha from Pfizer. The US- pharma outfit decided it did't want ATN-103, even though it met its goal in a mid-stage...

BeNeLuxBelgiumNetherlandsLuxembourg

25.10.2011

Amsterdam - The second blow could be the ultimate one. Amsterdam Molecular Therapeutics received a second negative opinion for Glybera to treat lipoprotein lipase (LPL) deficiency. The European Medicines Agency's (EMA) Committee...

BeNeLuxBelgiumNetherlandsLuxembourg

13.10.2011

Bilthoven – The current impact of hospital acquired infections with multi-resistant bugs is lower than suggested by startling news articles. According to a study of Dutch researchers, bloodstream infections caused by...

Displaying results 11 to 20 out of 304

< Previous 11-20 Next >

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/1/article/epo-enhancer-identified.html

Whitepaper

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ZEALAND PHARMA (DK)131.00 DKK10.08%
  • DIAMYD MEDICAL -B- (S)4.69 SEK8.56%
  • IPSEN (F)59.44 EUR6.68%

FLOP

  • MOLOGEN (D)2.05 EUR-10.87%
  • PHARMING (NL)0.22 EUR-8.33%
  • VALNEVA (F)2.40 EUR-4.38%

TOP

  • PROTHENA PLC (IE)55.41 USD58.5%
  • VERNALIS (UK)44.50 GBP31.9%
  • E-THERAPEUTICS (UK)13.50 GBP31.7%

FLOP

  • MOLOGEN (D)2.05 EUR-30.3%
  • SANTHERA (CH)55.00 CHF-28.5%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)31.20 SEK1850.0%
  • NICOX (F)10.49 EUR473.2%
  • SAREUM HOLDINGS (UK)0.77 GBP234.8%

FLOP

  • BB BIOTECH (D)44.84 EUR-84.6%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.78 SEK-78.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 29.07.2016

Events

All Events

Partner-Events